Products Brought to Market

One of the Foundations’ missions is to transfer resulting medical research discoveries from the laboratory to the use of the general public by patenting and licensing such technology for development into drugs or other products. The following medical products, which have been developed based on discoveries by the Clayton Foundation or its supporting organizations, have been brought to market:

Exparel

Post-surgical non-opioid pain relief

Exparel uses DepoFoam®, a proven product delivery technology, to deliver bupivacaine over 72 hours.

Learn More

Depocyt

Therapeutic drug for cancer

DEPOCYT is a sustained release formulation of cytarabine approved for the treatment of lymphomatous meningitis.

Learn More

Posicam Systems

PET imaging system

POSICAM™ systems incorporate patented and proprietary technology for the diagnosis and treatment of patients in the areas of oncology, cardiology and neurology.

Learn More

RetCam II & RetCam Shuttle

Digital ophthalmic medical device

RetCam II and RetCam Shuttle are a major achievement in providing minaturized, integrated, wide-field imaging for management of eye disorders in infants

Learn More

Depodur

Drug for time-released pain control

Depodur is the only extended-release morphine sulphate approved for epidural use in the treatment of postsurgical pain.

Learn More

FIA – Functional Intracellular Analysis

Lymphocyte blood assay

SpectraCell's FIA™ is a clinically effective diagnostic tool for the prevention and management of chronic disease conditions.

Learn More

SCA6 DNA Test



Autosomal Dominant Ataxia Evaluation and Complete Ataxia Evaluation

Neurogenetic diagnostic assay

Ataxia is characterized by poor coordination of hand, speech and eye movements, uncoordinated and unsteady gait. The test detects the triplet repeat expansion in nine known genes causing cerebellar ataxia, CAG triple repeat expansion in the SCA6 gene.

Learn More

Accuplex 4

Accuplex 4

The AccuPlex4 test for heartworm and the pathogens that cause Lyme disease, ehrlichiosis and anaplasmosis offers significant improvements in sensitivity and specificity over existing screening tests.

Learn More